• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    A

    Ablon Skin Institute and Research Center

    EST. 2008
    38论文总数
    641引用总数

    论文量&引用量时间轴

    机构学者

    论文(38)

    年份
    起
    –
    止
    排序
    176004 A NOVEL CREAM SIGNIFICANTLY IMPROVES SIGNS OF MATURE, AGING SKIN
    Glynis Ablon,Alan Widgerow,Thu Q. Nguyen,Sindhu Garimella,Christine Emesiani,Matthew Meckfessel
    2026JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    2RelaBoNT-A Treatment of Glabellar Lines and Lateral Canthal Lines of Different Baseline Severity: Subgroup Analyses of Pooled Phase III Study Data
    Glynis Ablon,Joel Schlessinger, Sachin Shridharani,Z. Paul Lorenc,Sherrif F. Ibrahim,Vince Bertucci,Leslie Baumann,Mark S. Nestor,Inna Prygova
    2026TOXICON(2026)
    引用
    AI阅读
    加入学术空间
    3The Safety and Efficacy of a Novel Saw Palmetto (serenoa Repens) Extract for Promoting Hair Growth in Adults with Self-Perceived Thinning Hair: 180-Day Results.
    Glynis Ablon

    BACKGROUND:Hair loss remains a global concern for both men and women. AIMS:This study assessed the efficacy and safety of a proprietary extract of bioactive fatty acids from saw palmetto (Serenoa repens) for treating self-perceived thinning hair in healthy adult men and women (SEREVELLE, Valensa International; Eustis, FL). METHODS:This 6-month, randomized, double-blind, placebo-controlled study assessed the beneficial effects of daily active treatment (n = 40) vs. placebo (n = 20) on several hair growth parameters. RESULTS:Active treatment of SEREVELLE significantly outperformed placebo on all primary endpoints at Day 180. Mean (SD) change in baseline total terminal hair count was +18.6 (29.6) with active vs. -10.1 (30.5) with placebo (p < 0.001; 283% greater improvement). Total vellus hair count increased +6.6 (15.6) vs. -2.1 (15.7) (p < 0.05; 414% greater improvement). Total hair density rose +25.1 (27.7) vs. -12.2 (38.8) (p < 0.001; 306% greater improvement). Subgroup analyses at Day 180 corroborated these advantages: across populations, between-group differences in mean change favored active for subgroup of men, with total terminal hair count (p = 0.003), total vellus hair count (p < 0.001), and total hair density (p < 0.001). In menopausal women, active produced significant placebo-adjusted gains in total terminal hair count (p < 0.05) and total hair density (p < 0.01), with a nonsignificant numerical advantage for total vellus hair count. There were no treatment-related adverse events. CONCLUSION:The daily use of a proprietary saw palmetto (Serenoa repens) extract safely and effectively promotes hair growth in men and women with self-perceived thinning hair.

    2026Journal of cosmetic dermatology(2026)
    引用
    AI阅读
    加入学术空间
    4Aesthetic Improvement of Glabellar Lines with Liquid RelabotulinumtoxinA Treatment in a 12-Month Randomized Controlled Study
    Joel Schlessinger,Joely Kaufman-Janette,Amir Moradi, Glynis R. Ablon, Younghoon R. Cho,Sue Ellen Cox,Robert A. Weiss,Edward Lain,Corey L. Hartman, Felipe A. Weinberg, Daniel Seisdedos Hedman, Sarah F. Coquis-Knezek

    Background: RelabotulinumtoxinA (relaBoNT-A) is a novel, complex-free, ready-to-use liquid BoNT-A for aesthetic use. Methods: This double-blind, Phase 3b study evaluated long-term (12-month) efficacy, satisfaction, safety, and time to onset of effect of relaBoNT-A for glabellar lines (GLs). Subjects were randomized 3:1 to a single dose of 50 U relaBoNT-A or placebo. Results: RelaBoNT-A was superior to placebo at Month 1 based on subject-reported Global Aesthetic Improvement Scale (GAIS) responder rates at maximum frown (primary endpoint), 92.9% (92/99 subjects) versus 9.1% (3/33 subjects), p<0.001. GAIS response after relaBoNT-A treatment remained high through Months 9 (42.7%) and 12 (37.8%), as did investigator-assessed GL severity (GL-ILA) ≥1-grade improvement at maximum frown at Months 6 (57.4%), 9 (28.1%), and 12 (12.2%). GAIS and GL-ILA showed onset of effect in 39.8% and 43.9% of relaBoNT-A-treated subjects within 1 day. Investigators reported increased confidence in dosing consistency with the ready-to-use product at baseline (98.0% relaBoNT-A vs. 100% placebo), and that they could achieve consistent (99.0% vs. 64.5%) and natural-looking results (98.0% vs. 64.5%) at Month 1. Subject satisfaction was higher for relaBoNT-A than placebo from Day 1 through Month 12. Two-thirds of subjects preferred treatment with relaBoNT-A to prior treatments with powder BoNT-As. Treatment-related adverse events (all mild) occurred in 8.1% of subjects. Conclusions: RelaBoNT-A showed rapid onset of effect from Day 1, with duration of effect through Month 6 for most subjects, and beyond 6 months for some. Injectors were highly satisfied with product usability, and subjects remained satisfied through Month 12. Treatment was well tolerated.

    2026Plastic &amp Reconstructive Surgery(2026)
    引用
    AI阅读
    加入学术空间
    574752 the Influence of Age on Relabotulinumtoxina Outcomes in Moderate-to-severe Glabellar and Lateral Canthal Lines: Post-Hoc Analysis of Three Phase 3 Double-Blind, Placebo-Controlled Trials
    Glynis Ablon,Heidi Prather, Sherrif Ibrahim,Paul Lorenc,Joel Schlessinger,Jason Rivers, Aamir Moradi,Sarah Coquis-Knezek,Matthew Meckfessel
    2026Journal of the American Academy of Dermatology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 38 篇论文

    合作机构(21)

    Galderma Inc.合作论文 5
    Denova Research合作论文 4
    Maryland Dermatology Laser Skin and Vein Institute合作论文 3
    Institute for Skin Research (Israel)合作论文 3
    弗里曼商学院合作论文 2
    Center for Clinical and Cosmetic Research合作论文 2
    Center for Dermatology and Laser Surgery合作论文 1
    cedars-sinai 医疗中心合作论文 1
    Tennessee Clinical Research Center合作论文 1
    华盛顿大学合作论文 1

    机构统计